About this trial
The survival interval of patients with gliomas ranges between 12 to 15 months. Recent findings revealed that dietary interventions to reduce glucose and glycolytic pathways could have a therapeutic effect. Ketosis can be an effective therapy to extend the survival of patients with gliomas.
Eligibility criteria
Qualifiers
Age 18-80
Karnofsky Performance Score of 50 or more.
Newly diagnosed, histologically confirmed glioblastoma grade 4, or secondary metastases or progression after surgical resection, radiation and chemotherapy.
Normal function of liver and kidneys
Disqualifiers
Diabetes mellitus
Life expectancy >3 months
Inability to adhere to diet
Inability to give informed consent form
Trial design
Treatments tested in this trial
- CKD
Treatment groups
15 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov